Anxo Pharmaceutical Co., Ltd.
Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally. The company offers prescription and over the counter drugs in various therapeutic areas, such as cardiovascular, metabolism, CNS, diabetic, respiratory, anti-infection, dermatology, nephrology, urology, o… Read more
Anxo Pharmaceutical Co., Ltd. (6677) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.011x
Based on the latest financial reports, Anxo Pharmaceutical Co., Ltd. (6677) has a cash flow conversion efficiency ratio of -0.011x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-12.83 Million) by net assets (NT$1.12 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Anxo Pharmaceutical Co., Ltd. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Anxo Pharmaceutical Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Anxo Pharmaceutical Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anxo Pharmaceutical Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HIPAY GROUP INH. EO 4-
F:9LH
|
N/A |
|
VULCAN MINLS
F:VM3
|
N/A |
|
Lii Hen Industries Bhd
KLSE:7089
|
0.033x |
|
MorphoSys AG
PINK:MPSYF
|
0.246x |
|
Circio Holding ASA
OL:CRNA
|
2.069x |
|
Openn Negotiation Limited
PINK:OPNNF
|
2.928x |
|
Primega Group Holdings Limited
NASDAQ:ZDAI
|
0.026x |
|
LiCycle Holdings Corp
NYSE:LICY
|
-0.069x |
Annual Cash Flow Conversion Efficiency for Anxo Pharmaceutical Co., Ltd. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Anxo Pharmaceutical Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.14 Billion | NT$111.97 Million | 0.098x | +4553.79% |
| 2023-12-31 | NT$1.20 Billion | NT$-2.65 Million | -0.002x | -102.57% |
| 2022-12-31 | NT$829.64 Million | NT$71.27 Million | 0.086x | -8.79% |
| 2021-12-31 | NT$831.94 Million | NT$78.35 Million | 0.094x | +27.63% |
| 2020-12-31 | NT$811.46 Million | NT$59.88 Million | 0.074x | -21.17% |
| 2019-12-31 | NT$688.79 Million | NT$64.48 Million | 0.094x | -- |